Oncodesign and TiumBio sign a collaboration agreement for the R&D of candidate drugs against fibrosis
DIJON, France & PANGYO, South Korea – (COMMERCIAL THREAD) – Regulatory news:
Oncodesign (ALONC – FR0011766229), a French biopharmaceutical company specializing in research on kinase inhibitors and precision medicine, and TiumBio (KOSDAQ: 321550), a company specializing in R&D for rare diseases, announced the signing of a research collaboration agreement on the R&D of potential drug candidates for fibrosis.
Under this agreement, Oncodesign will be responsible for the identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early stage analysis, while TiumBio will be responsible for the advanced evaluation of the fibrotic efficacy of drug candidates. This first phase of the collaboration will be financed by TiumBio.
In addition, TiumBio has obtained an exclusive option to license the worldwide rights to develop and commercialize drug candidates discovered after their evaluation after reaching predefined success criteria. The financial terms of this option, which could be lifted during the next year, cannot be disclosed at this stage.
Hun-Taek Kim, CEO of TiumBio, said: “We are delighted to be working with Oncodesign to achieve our common goal of developing treatments for rare and incurable diseases. If we combine Oncodesign’s kinase inhibitor-based platform technology and our experience and expertise in R&D focused on fibrosis in rare diseases, I am confident that we can develop new innovative drugs in the field of fibrosis.
Philippe Genne, CEO and founder of Oncodesign, said: “This new collaboration with TiumBio, a fibrosis expert company in South Korea, further expands the global reach of our unique technologies. After previous collaborations with international pharmaceutical companies such as BMS (Bristol-Myers-Squibb), Ipsen, Sanofi, Servier and UCB, our Nanocyclix® technology platform is once again ready to provide solutions in a difficult area. I am delighted to team up with TiumBio to find solutions for patients with fibrosis.
Jan Hoflack, Oncodesign CSO, added: “This agreement is another example where an expert pharmaceutical company looking for compounds with unique and difficult criteria has just benefited from our Nanocyclix® technology platform, in search of high potency and exquisite selectivity. The initial testing of the Nanocyclix® diversity set identified starting points that met the initial TiumBio criteria and led to this exciting collaboration.
Fibrosis occurs in most of the tissues of the human body, which is a phenomenon of the formation of fibrous connective tissue. As the disease progresses, the function of the corresponding organ is defective, which can lead to various fatal chronic diseases such as pulmonary and hepatic fibrosis. In addition, fibrosis accounts for approximately 45% of all-cause disease mortality.1, and as there are currently few effective treatments, this is a pathological area with a very high unmet medical demand from patients.
In 2018, TiumBio licensed the patent right of ‘NCE401’, a drug candidate that was in the preclinical stage for the treatment of pulmonary fibrosis, to Chiesi Farmaceutici, an Italian pharmaceutical company. Last year, the drug candidate for the treatment of NASH was selected as a government project BIG3. In addition, it has a number of new and developing fibrosis pipelines, and is known to conduct R&D activities to expand indication areas such as hepatic and renal fibrosis. It is believed that this joint R&D collaboration, signed by TiumBio, which has strengths in R&D on fibrosis, may be a catalyst to stimulate the development of the treatment of fibrosis.
Oncodesign is a biopharmaceutical company dedicated to precision medicine, founded in 1995 by its current CEO and majority shareholder, and listed on the Euronext Growth Market since April 2014. Its mission is to discover effective therapies to fight cancer and others. diseases without therapeutic solutions. . With its unique experience acquired by working with more than 1,000 clients, including the world’s largest pharmaceutical companies, as well as its unique technological platform combining Artificial Intelligence, cutting-edge medicinal chemistry, pharmacology, regulated bioanalysis, medical imaging, Oncodesign is in able to select new therapeutic targets, design and develop potential preclinical candidates up to clinical phases. Oncodesign has configured its organization to offer innovative services to its customers and license its proprietary molecules. Applied to kinase inhibitors, which represent a market estimated at more than 65 billion dollars by 2027 and representing nearly 25% of the R&D expenditure of the pharmaceutical industry, Oncodesign’s technology has already made it possible to target several molecules. promising companies with strong therapeutic potential, in oncology and elsewhere, as well as partnerships with global pharmaceutical groups. Oncodesign is based in Dijon, France, at the heart of the city’s university and hospital hub, and within the Paris-Saclay hub. Oncodesign has 233 employees within 3 Business Units (BU): Service, Biotech, Artificial Intelligence and subsidiaries in Canada and the USA. www.oncodesign.com
This press release contains certain forward-looking statements and estimates concerning the financial condition, results of operations, strategy, plans and future performance of the Company and the markets in which it operates. These forward-looking statements and estimates may be identified by words such as “anticipate”, “believe”, “may”, “could”, “estimate”, “expect”, “intend”, “is designed to “,” May, “” could “,” plan “,” potential “,” predict “,” goal “,” should “, or the negative of these expressions and the like. They incorporate all matters that are not facts Forward-looking statements, forecasts and estimates are based on management’s current assumptions and on the assessment of risks, uncertainties and other factors, known and unknown, which were considered reasonable at the time they were made, but which may prove to be incorrect. Events and results are difficult to predict and depend on factors beyond the control of the Company. Consequently, the actual results, financial condition, performance and / or achievements of the Company or industry can ave differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Due to these uncertainties, no representation is made as to the accuracy or fairness of these forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and the Company assumes no obligation to update or revise any of them, whether whether as a result of new information, future events or otherwise, except as required by law.
1 Nature 587, 555-566 (2020)